Robert P Hasserjian

List of Publications by Year
in descending order

142	14,379	159585 30	22166 113
papers	citations	h-index	g-index

149	149	149	14888
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal. Blood, 2022, 139, 323-332.	1.4	80
2	Global Cytopathology-Hematopathology Practice Trends. American Journal of Clinical Pathology, 2022, 157, 196-201.	0.7	4
3	Lymph node FNA cytology: Diagnostic performance and clinical implications of proposed diagnostic categories. Cancer Cytopathology, 2022, 130, 144-153.	2.4	8
4	This Yearâ€™s Best in Hematology Diagnosis: A New Disease Is Discovered. , 2022, 19, .		2
5	TP53 mutation defines a unique subgroup within complex karyotype deÂnovo and therapy-related MDS/AML. Blood Advances, 2022, 6, 2847-2853.	5.2	87
6	Primary Central Nervous System Anaplastic Large Cell Lymphoma, ALK Positive. American Journal of Clinical Pathology, 2022, 158, 300-310.	0.7	4
7	Survival of the Fittest: Hypomethylating Agent/BCL-2 Inhibitor Combination Versus Intensive Chemotherapy As Frontline Treatment for Acute Myeloid Leukemia. , 2022, 19, .		0
8	Bedside to Bench and Back: Identifying a New Clinically Relevant Driver in Pediatric Acute Myeloid Leukemia. Blood Cancer Discovery, 2022, , .	5.0	1
9	Guiding the global evolution of cytogenetic testing for hematologic malignancies. Blood, 2022, 139, 2273-2284.	1.4	29
10	TP53-mutated Acute Myeloid Leukemia and Myelodysplastic Syndrome With Excess Blasts: Two Sides of the Same Coin?. , 2022, 19, .		0
11	ALK-positive Histiocytosis: An Old Target Shows Up in a New Disguise. , 2022, 19, .		0
12	Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. , 2022, 1, .		259
13	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood, 2022, 140, 1200-1228.	1.4	814
14	Revealing the dark secrets of TP53-mutated AML. Blood, 2022, 140, 8-10.	1.4	2
15	Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood, 2022, 140, 1345-1377.	1.4	805
16	Genomic alterations in patients with somatic loss of the Y chromosome as the sole cytogenetic finding in bone marrow cells. Haematologica, 2021, 106, 555-564.	3.5	34
17	Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1. Modern Pathology, 2021, 34, 20-31.	5.5	9
18	Ocular adnexal lymphoma: long-term outcome, patterns of failure and prognostic factors in 174 patients. Journal of Hematopathology, 2021, 14, 41-52.	0.4	1

#	Article	IF	Citations
19	Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group. Modern Pathology, 2021, 34, 1358-1366.	5.5	8
20	Flow cytometry reveals the nuances of clonal haematopoiesis. British Journal of Haematology, 2021, 192, 949-950.	2.5	1
21	JAK2 Rearrangements Are a Recurrent Alteration in CD30+ Systemic T-Cell Lymphomas With Anaplastic Morphology. American Journal of Surgical Pathology, 2021, 45, 895-904.	3.7	29
22	Navigating Myelodysplastic and Myelodysplastic/Myeloproliferative Overlap Syndromes. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 328-350.	3.8	2
23	Controversies in the recent (2016) World Health Organization classification of acute myeloid leukemia. Best Practice and Research in Clinical Haematology, 2021, 34, 101249.	1.7	9
24	A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML. Blood Advances, 2021, 5, 2279-2283.	5.2	2
25	Multiorgan failure in a fatal case of autoimmune hemolytic anemia. Transfusion, 2021, 61, 2795-2798.	1.6	3
26	Myeloid/lymphoid neoplasms with FLT3 rearrangement. Modern Pathology, 2021, 34, 1673-1685.	5.5	21
27	Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML. Blood Advances, 2021, 5, 2539-2549.	5.2	9
28	The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13. Blood, 2021, 138, 1870-1884.	1.4	20
29	Myelodysplastic syndromes with no somatic mutations detected by nextâ€generation sequencing display similar features to myelodysplastic syndromes with detectable mutations. American Journal of Hematology, 2021, 96, E420-E423.	4.1	5
30	Erythroid nuclear dysplasia is associated with inferior outcomes for patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation. Leukemia Research, 2021, 109, 106625.	0.8	0
31	Case 33-2021: A 68-Year-Old Man with Painful Mouth Ulcers. New England Journal of Medicine, 2021, 385, 1700-1710.	27.0	1
32	TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes. Cancers, 2021, 13, 5502.	3.7	2
33	Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. Modern Pathology, 2021, , .	5.5	9
34	Changes in ABC Transporter Expression during Hematopoiesis Cause Lineage-Biased Cytopenias in Patients Treated with Aurora Kinase Inhibitors. Blood, 2021, 138, 4292-4292.	1.4	0
35	Oligoblastic (<20%) Myeloid Neoplasms with KMT2A (MLL) Rearrangement Show Significant Overlap with Acute Myeloid Leukemia (AML) and Should be Regarded As AML. Blood, 2021, 138, 793-793.	1.4	1
36	A phase 1 study of the antibodyâ€drug conjugate brentuximab vedotin with reâ€induction chemotherapy in patients with CD30â€expressing relapsed/refractory acute myeloid leukemia. Cancer, 2020, 126, 1264-1273.	4.1	15

#	Article	IF	Citations
37	Detection of the KITD816V mutation in myelodysplastic and/or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosis. Modern Pathology, 2020, 33, 1135-1145.	5.5	12
38	Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis. Blood, 2020, 136, 3051-3055.	1.4	15
39	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature Medicine, 2020, 26, 1549-1556.	30.7	372
40	Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia. Blood, 2020, 135, 1729-1738.	1.4	80
41	Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with increased blasts (<10%) or with other types of disease progression. Haematologica, 2020, 105, e221-e224.	3.5	8
42	How I Diagnose Low-Grade Myelodysplastic Syndromes. American Journal of Clinical Pathology, 2020, 154, 5-14.	0.7	9
43	Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1â€“KMT2Aâ€“YAP1 and VIMâ€“KMT2A fusions. Modern Pathology, 2020, 33, 2307-2317.	5.5	24
44	Bone marrow niches in haematological malignancies. Nature Reviews Cancer, 2020, 20, 285-298.	28.4	270
45	Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia. Leukemia, 2020, 34, 2025-2037.	7.2	27
46	Multiparametric in situ imaging of NPM1-mutated acute myeloid leukemia reveals prognostically-relevant features of the marrow microenvironment. Modern Pathology, 2020, 33, 1380-1388.	5.5	9
47	On-chip recapitulation of clinical bone marrow toxicities and patient-specific pathophysiology. Nature Biomedical Engineering, 2020, 4, 394-406.	22.5	170
48	Comparison of therapyâ€related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study. American Journal of Hematology, 2020, 95, 799-808.	4.1	26
49	Concordance among hematopathologists in classifying blasts plus promonocytes: A bone marrow pathology group study. International Journal of Laboratory Hematology, 2020, 42, 418-422.	1.3	21
50	Identification of germline variants in adults with hemophagocytic lymphohistiocytosis. Blood Advances, 2020, 4, 925-929.	5.2	8
51	The current approach to the diagnosis of myelodysplastic syndromesâ˜†. Seminars in Hematology, 2019, 56, 15-21.	3.4	22
52	Composite chronic myeloid leukemia and essential thrombocythemia with BCRâ€ABL1 fusion and CALR mutation. American Journal of Hematology, 2019, 94, 504-505.	4.1	9
53	Premalignant Clonal Hematopoietic Proliferations. American Journal of Clinical Pathology, 2019, 152, 347-358.	0.7	3
54	Genetic Testing in the Diagnosis and Biology of Myeloid Neoplasms (Excluding Acute Leukemias). American Journal of Clinical Pathology, 2019, 152, 302-321.	0.7	5

#	Article	IF	Citations
55	High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia. American Journal of Hematology, 2019, 94, 921-928.	4.1	24
56	Gene expression profiling distinguishes prefibrotic from overtly fibrotic myeloproliferative neoplasms and identifies disease subsets with distinct inflammatory signatures. PLoS ONE, 2019, 14, e0216810.	2.5	20
57	Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. Modern Pathology, 2019, 32, 1373-1385.	5.5	25
58	Characterization of applicants for residency training in pathology: Does diversity exist?. Annals of Diagnostic Pathology, 2019, 40, 23-25.	1.3	3
59	Illuminating neutrophilic myeloid neoplasms. Blood, 2019, 134, 846-848.	1.4	6
60	Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms. Blood Advances, 2019, 3, 1540-1545.	5.2	44
61	Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome. Blood Advances, 2019, 3, 3322-3332.	5.2	20
62	Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms. Human Pathology, 2019, 86, 1-11.	2.0	24
63	Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study. Modern Pathology, 2019, 32, 490-498.	5.5	50
64	TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes. Blood, 2019, 134, 675-675.	1.4	17
65	Bone Marrow Morphologic Findings in Patients Receiving IDH Inhibitor Therapy in Combination with Intensive Induction Chemotherapy: Challenges with Interpretation of the Day 14 Bone Marrow Biopsy. Blood, 2019, 134, 1442-1442.	1.4	0
66	A reevaluation of erythroid predominance in Acute Myeloid Leukemia using the updated WHO 2016 Criteria. Modern Pathology, 2018, 31, 873-880.	5.5	3
67	A distinct immunophenotype identifies a subset of NPM1â€mutated AML with TET2 or IDH1/2 mutations and improved outcome. American Journal of Hematology, 2018, 93, 504-510.	4.1	36
68	Changes in the World Health Organization 2016 classification of myeloid neoplasms everyone should know. Current Opinion in Hematology, 2018, 25, 120-128.	2.5	4
69	Association of mutations with morphological dysplasia in de novo acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities. Haematologica, 2018, 103, 626-633.	3.5	20
70	High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood, 2018, 131, 2816-2825.	1.4	64
71	JAK2 , CALR , MPL and ASXL1 mutational status correlates with distinct histological features in Philadelphia chromosome-negative myeloproliferative neoplasms. Haematologica, 2018, 103, e63-e68.	3.5	13
72	tp53 deficiency causes a wide tumor spectrum and increases embryonal rhabdomyosarcoma metastasis in zebrafish. ELife, 2018, 7, .	6.0	51

#	Article	IF	Citations
73	Nuclear IHC enumeration: A digital phantom to evaluate the performance of automated algorithms in digital pathology. PLoS ONE, 2018, 13, e0196547.	2.5	7
74	JAK2 V617Fâ€positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group. British Journal of Haematology, 2018, 182, 78-85.	2.5	22
75	Diagnostic algorithm for lower-risk myelodysplastic syndromes. Leukemia, 2018, 32, 1679-1696.	7.2	10
76	PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study. Blood, 2018, 132, 686-686.	1.4	44
77	Phase I Study of the Antibody-Drug Conjugate Brentuximab Vedotin Combined with Re-Induction Chemotherapy in Patients with CD30-Expressing Relapsed/Refractory Acute Myeloid Leukemia. Blood, 2018, 132, 1431-1431.	1.4	0
78	Clinical, Immunophenotypic and Genomic Findings of Acute Undifferentiated Leukemia and Comparison to AML with Minimal Differentiation: A Study from the Bone Marrow Pathology Group. Blood, 2018, 132, 1491-1491.	1.4	0
79	Clinicopathologic evaluation of cytopenic patients with isolated trisomy 8: a detailed comparison between idiopathic cytopenia of unknown significance and low-grade myelodysplastic syndrome. Leukemia and Lymphoma, 2017, 58, 569-577.	1.3	12
80	Prognostic Significance of Residual Acute Myeloid Leukemia in Bone Marrow Samples Taken Prior to Allogeneic Hematopoietic Cell Transplantation. American Journal of Clinical Pathology, 2017, 147, aqw203.	0.7	2
81	Computerâ€assisted quantification of CD3+ T cells in follicular lymphoma. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2017, 91, 609-621.	1.5	5
82	Assessment of myeloid and monocytic dysplasia by flow cytometry in de novo AML helps define an AML with myelodysplasia-related changes category. Journal of Clinical Pathology, 2017, 70, 109-115.	2.0	7
83	Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. Haematologica, 2017, 102, 1352-1360.	3.5	62
84	Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 30 chronic myelomonocytic leukemia. Modern Pathology, 2017, 30, 1213-1222.	5.5	52
85	Myelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis. American Journal of Clinical Pathology, 2017, 148, 49-57.	0.7	18
86	NPM1 mutation but not RUNX1 mutation or multilineage dysplasia defines a prognostic subgroup within de novo acute myeloid leukemia lacking recurrent cytogenetic abnormalities in the revised 2016 WHO classification. American Journal of Hematology, 2017, 92, E123-E124.	4.1	11
87	Ring chromosome in myeloid neoplasms is associated with complex karyotype and disease progression. Human Pathology, 2017, 68, 40-46.	2.0	5
88	European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia. American Journal of Hematology, 2017, 92, 1062-1067.	4.1	33
89	Most Myeloid Neoplasms With Deletion of Chromosome 16q Are Distinct From Acute Myeloid Leukemia With Inv(16)(p13.1q22). American Journal of Clinical Pathology, 2017, 147, 411-419.	0.7	6
90	Primary lymphoma of bone in the pediatric and young adult population. Human Pathology, 2017, 60, 1-10.	2.0	31

#	Article	IF	Citations
91	Cytogenetic evolution between diagnosis and relapse and impact on acute myeloid leukemia (AML) reinduction outcomes.. Journal of Clinical Oncology, 2017, 35, e18509-e18509.	1.6	1
92	Smallâ€cell predominant extranodal <scp>NK</scp>/T cell lymphoma, nasal type: clinicopathological analysis of a series of cases diagnosed in a Western population. Histopathology, 2016, 69, 667-679.	2.9	20
93	Case 37-2016. New England Journal of Medicine, 2016, 375, 2273-2282.	27.0	3
94	Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. Modern Pathology, 2016, 29, 854-864.	5.5	104
95	Pure Erythroid Leukemia and Erythroblastic Sarcoma Evolving From Chronic Myeloid Neoplasms. American Journal of Clinical Pathology, 2016, 145, 538-551.	0.7	24
96	Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations. Blood, 2016, 128, 1093-1100.	1.4	126
97	Molecular testing for <scp>JAK</scp>2, <scp>MPL</scp>, and <scp>CALR</scp> in myeloproliferative neoplasms. American Journal of Hematology, 2016, 91, 1277-1280.	4.1	21
98	The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 2016, 127, 2391-2405.	1.4	7,429
99	Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts. Modern Pathology, 2016, 29, 1221-1231.	5.5	22
100	Genetic Testing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Surgical Pathology Clinics, 2016, 9, 143-163.	1.7	14
101	Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response. Leukemia and Lymphoma, 2016, 57, 812-819.	1.3	7
102	Examination of Phosphoprotein Targets in Timed Samples from Patients with RAS-Mutated AML during Concurrent Treatment with Alpelisib and Binimetinib on the Phase Ib Clinical Trial CMEK162X2109. Blood, 2016, 128, 2749-2749.	1.4	0
103	Resistant T-Cell Acute Lymphoblastic Leukemias That Emerge after In Vivo Treatment with Dexamethasone Frequently Down-Regulate Glucocorticoid Receptor Protein Expression. Blood, 2016, 128, 753-753.	1.4	7
104	TP53 Immunostaining in Double-Hit and Double-Expressing High-Grade B-Cell Lymphoma. Blood, 2016, 128, 1876-1876.	1.4	0
105	Routine conventional karyotyping of lymphoma staging bone marrow samples does not contribute clinically relevant information. American Journal of Hematology, 2015, 90, 529-533.	4.1	5
106	Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. Journal of Translational Medicine, 2015, 13, 294.	4.4	36
107	Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia. Modern Pathology, 2015, 28, 965-976.	5.5	31
108	Acute Erythroleukemias, Acute Megakaryoblastic Leukemias, and Reactive Mimics. American Journal of Clinical Pathology, 2015, 144, 44-60.	0.7	43

#	Article	IF	Citations
109	Acute myeloid leukemia in a patient with constitutional 47,XXY karyotype. Leukemia Research Reports, 2015, 4, 28-30.	0.4	0
110	Impact of Bone Marrow Pathology on the Clinical Management of Philadelphia Chromosomeâ€“Negative Myeloproliferative Neoplasms. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 253-261.	0.4	16
111	Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood, 2015, 126, 9-16.	1.4	1,493
112	Chronic lymphocytic leukemia/small lymphocytic lymphoma: another neoplasm related to the B-cell follicle?. Leukemia and Lymphoma, 2015, 56, 3378-3386.	1.3	7
113	Diagnostic Yield of CT-Guided Percutaneous Transthoracic Needle Biopsy for Diagnosis of Anterior Mediastinal Masses. American Journal of Roentgenology, 2015, 205, 774-779.	2.2	54
114	Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Journal of Molecular Diagnostics, 2015, 17, 661-668.	2.8	31
115	Prior cytopenia predicts worse clinical outcome in acute myeloid leukemia. Leukemia Research, 2015, 39, 1034-1040.	0.8	8
116	High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome. Modern Pathology, 2015, 28, 552-563.	5.5	42
117	PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks. Blood, 2015, 126, 56-56.	1.4	28
118	Pediatric-Type Nodal Follicular Lymphoma in Children and Adults Is Nearly Genetically Silent and Biologically Distinct from Typical Follicular Lymphoma. Blood, 2015, 126, 3925-3925.	1.4	0
119	Diverse Clinicopathologic Features in Human Herpesvirus 8â€“Associated Lymphomas Lead to Diagnostic Problems. American Journal of Clinical Pathology, 2014, 142, 816-829.	0.7	55
120	High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms. Modern Pathology, 2014, 27, 1447-1454.	5.5	24
121	Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. Haematologica, 2014, 99, 821-829.	3.5	61
122	Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results. Blood, 2014, 124, 713-713.	1.4	31
123	Differential regulation of myeloid leukemias by the bone marrow microenvironment. Nature Medicine, 2013, 19, 1513-1517.	30.7	233
124	Erythroleukemia and Its Differential Diagnosis. Surgical Pathology Clinics, 2013, 6, 641-659.	1.7	9
125	Inter-reader variability in follicular lymphoma grading: Conventional and digital reading. Journal of Pathology Informatics, 2013, 4, 30.	1.7	20
126	Effect Of Treatment With The JAK2-Selective Inhibitor Fedratinib (SAR302503) On Bone Marrow Histology In Patients With Myeloproliferative Neoplasms With Myelofibrosis. Blood, 2013, 122, 2823-2823.	1.4	15

#	Article	IF	Citations
127	Differential Regulation of Myeloid Leukemias by the Bone Marrow Microenvironment. Blood, 2012, 120, 1245-1245.	1.4	1
128	Clinicopathologic Characterization of Acute Myeloid Leukemia and Myelodysplastic Syndrome with Inv(3)(q21q26.2)/t(3;3)(q21;q26.2) Reveals That Complex Karyotype but Not Blast Percentage Is Associated with Poor Survival; A Bone Marrow Pathology Group Study. Blood, 2012, 120, 3847-3847.	1.4	0
129	Chronic myelogenous leukemia in the age of imatinib: assessing response, acceleration, and blast phase. Journal of Hematopathology, 2011, 4, 81-92.	0.4	1
130	Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) with CD30-positive lymphocyte-predominant (LP) cells. Journal of Hematopathology, 2011, 4, 175-181.	0.4	11
131	Parathyroid Hormone-Induced Modulation of the Bone Marrow Microenvironment Reduces Leukemic Stem Cells in Murine Chronic Myelogenous-Leukemia-Like Disease Via a TGFbeta-Dependent Pathway. Blood, 2011, 118, 1670-1670.	1.4	1
132	Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. Blood, 2010, 115, 1985-1992.	1.4	97
133	Evidence of Long Latency Periods Prior to Development of Mantle Cell Lymphoma. Blood, 2010, 116, 323-323.	1.4	9
134	Response to Dasatinib In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Correlates with p-Lyn and p-Syk. Blood, 2010, 116, 2457-2457.	1.4	0
135	Immunomodulator agent-related lymphoproliferative disorders. Modern Pathology, 2009, 22, 1532-1540.	5.5	74
136	Niche Induced Myelodysplasia and Secondary Hematopoietic Neoplasia Caused by Deletion of Dicer1 in Osteoprogenitor Cells.. Blood, 2009, 114, 247-247.	1.4	0
137	Evaluation of Bone Marrow Reticulin Formation in Romiplostim-Treated Adult Patients with Chronic Immune Thrombocytopenic Purpura (ITP).. Blood, 2008, 112, 3416-3416.	1.4	2
138	Reactive Versus Neoplastic Bone Marrow: Problems and Pitfalls. Archives of Pathology and Laboratory Medicine, 2008, 132, 587-594.	2.5	14
139	Philadelphia Chromosome-Positive Acute Myeloid Leukemia: A Rare Aggressive Leukemia With Clinicopathologic Features Distinct From Chronic Myeloid Leukemia in Myeloid Blast Crisis. American Journal of Clinical Pathology, 2007, 127, 642-650.	0.7	1
140	Precursor B Lymphoblastic Lymphoma Restricted to the Central Nervous System: A Case Report. FASEB Journal, 2007, 21, A391.	0.5	0
141	Bone Marrow Reticulin in Patients with Immune Thrombocytopenic Purpura.. Blood, 2006, 108, 3982-3982.	1.4	18
142	Philadelphia Chromosome Positive Acute Myeloid Leukemia: An Aggressive Acute Leukemia with Clinicopathologic Features Distinct from Chronic Myeloid Leukemia in Blast Crisis.. Blood, 2005, 106, 3290-3290.	1.4	0